Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04675294
Title Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ALX Oncology Inc.
Indications

head and neck squamous cell carcinoma

Therapies

Evorpacept + Pembrolizumab

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | ESP | CAN | BEL


No variant requirements are available.